Rigel Pharmaceuticals (RIGL)
(Real Time Quote from BATS)
$1.14 USD
0.00 (0.00%)
Updated Apr 24, 2024 12:40 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
RIGL 1.14 0.00(0.00%)
Will RIGL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RIGL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RIGL
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
RIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
Other News for RIGL
12 Health Care Stocks Moving In Monday's After-Market Session
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Rigel Pharmaceuticals' olutasidenib shows efficacy in published AML study
Commit To Buy Rigel Pharmaceuticals At $1, Earn 20.1% Annualized Using Options